EWTX vs. KURA, ZGNX, ARCT, XENT, ANAB, SMMT, OGN, IONS, BBIO, and CYTK
Should you be buying Edgewise Therapeutics stock or one of its competitors? The main competitors of Edgewise Therapeutics include Kura Oncology (KURA), Zogenix (ZGNX), Arcturus Therapeutics (ARCT), Intersect ENT (XENT), AnaptysBio (ANAB), Summit Therapeutics (SMMT), Organon & Co. (OGN), Ionis Pharmaceuticals (IONS), BridgeBio Pharma (BBIO), and Cytokinetics (CYTK). These companies are all part of the "medical" sector.
Edgewise Therapeutics (NASDAQ:EWTX) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment, community ranking and earnings.
Kura Oncology received 383 more outperform votes than Edgewise Therapeutics when rated by MarketBeat users. Likewise, 69.01% of users gave Kura Oncology an outperform vote while only 62.50% of users gave Edgewise Therapeutics an outperform vote.
Edgewise Therapeutics' return on equity of -29.09% beat Kura Oncology's return on equity.
Edgewise Therapeutics presently has a consensus price target of $31.20, suggesting a potential upside of 82.14%. Kura Oncology has a consensus price target of $27.94, suggesting a potential upside of 35.55%. Given Edgewise Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Edgewise Therapeutics is more favorable than Kura Oncology.
In the previous week, Kura Oncology had 1 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 3 mentions for Kura Oncology and 2 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.89 beat Kura Oncology's score of 0.69 indicating that Edgewise Therapeutics is being referred to more favorably in the media.
Edgewise Therapeutics has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500.
Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.
Summary
Edgewise Therapeutics beats Kura Oncology on 7 of the 13 factors compared between the two stocks.
Get Edgewise Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Edgewise Therapeutics Competitors List
Related Companies and Tools
